Phase 2 Multiple Sclerosis Clinical Trials
37 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 37 trials
Recruiting
Phase 1Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 2
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Cairo University46 enrolled1 locationNCT06599307
Recruiting
Phase 1Phase 2
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco74 enrolled1 locationNCT05359653
Recruiting
Phase 2
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
Hoffmann-La Roche12 enrolled17 locationsNCT07161258
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled16 locationsNCT07282574
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled53 locationsNCT06782490
Recruiting
Phase 1Phase 2
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06617793
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled41 locationsNCT07074886
Recruiting
Phase 1Phase 2
Molecular Imaging of NET Using [C-11]MRB-PET in MS
Multiple Sclerosis
Brigham and Women's Hospital19 enrolled1 locationNCT03207464
Recruiting
Phase 1Phase 2
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Multiple SclerosisAlzheimer s Disease
Brigham and Women's Hospital250 enrolled1 locationNCT02649985
Recruiting
Phase 2
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple SclerosisClinically Isolated Syndrome of Demyelination
Queen Mary University of London40 enrolled2 locationsNCT05418010
Recruiting
Phase 2
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Multiple Sclerosis
ModernaTX, Inc.180 enrolled17 locationsNCT06735248
Recruiting
Phase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Multiple Sclerosis
Eli Lilly and Company200 enrolled50 locationsNCT06220669
Recruiting
Phase 2
Ketamine for Multiple Sclerosis Fatigue
Multiple Sclerosis Fatigue
Johns Hopkins University110 enrolled1 locationNCT05378100
Recruiting
Phase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
State University of New York at Buffalo30 enrolled1 locationNCT06463743
Recruiting
Phase 1Phase 2
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Progressive Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06675864
Recruiting
Phase 2
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD54 enrolled7 locationsNCT06292923
Recruiting
Phase 2
Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
InsomniaMultiple Sclerosis
University of Kansas Medical Center90 enrolled1 locationNCT06434571
Recruiting
Phase 2
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)30 enrolled1 locationNCT02784210